ONO-2017-02:An Open-Label Extension study of Cenobamate in Japanese Subjects with Partial Onset Seizures

ONO-2017-02:A Phase 2, Multicenter Open-Label Extension Study to Evaluate the Long-term Safety of Cenobamate in Japanese Subjects with Partial Onset Seizures

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031220198

Enrollment

100

Registered

2022-07-08

Start date

2022-11-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Partial Onset Seizures with epilepsy

Interventions

Subjects will start initial dose as same as the lastdose from YKP3089C035 study. Doses may be decreased or subsequently increased in 50 mg/day decrements or increments, with the minimum and maximum do

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects completed Study YKP3089C035 by SK Life Science.

Exclusion criteria

Exclusion criteria: 1.Subjects that have previously discontinued for any reason from the Core study (YKP3089C035). 2.Any significant changes to the medical history of the subject that in the opinion of the investigator, could affect the safety of the subject.

Design outcomes

Primary

Measure	Time frame
Safety and tolerability	—

Secondary

Measure	Time frame
Efficacy (seizure frequency)	—

Contacts

Public ContactSupport Desk JP

Ono Pharmaceutical Co.,LTD

clinical_trial@ono-pharma.com+81-120-278-120

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026